Company Background
Axcentua was founded in September 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt. The team has more than 30 years of experience from leading positions in the pharmaceautical and biotech industry together with a proven track-record of bringing compounds from discovery to early clinical proof-of-concept studies. The strong management skills, documented scientific knowledge and drug development know-how together with a network of complementary clinical, business development and intellectual property expertise makes Axcentua´s management a powerful and committed team.

Stefan Rehnmark, CEO - PhD in Physiology 1991, Research Fellow Harvard Medical School 1989 -1990, Postdoctoral Fellow UCLA 1992 -1994, Assistant Professor Wenner-Gren Institute 1994 -1998, Associate Professor Wenner-Gren Institute 2000, 10 years of experience from Biotech, holding several positions, such as Project Manager, Head of Pharmacology and most recent Principal Scientist Target Validation.

Michael-Robin Witt, CSO - He graduated in 1986 with an MSc. in Biochemistry at the Freie Universität Berlin and subsequently engaged in Neuropharmacological research at the Research Laboratory of St. Hans Hospital, Roskilde, Denmark, obtaining a Ph.D. in Neuropharmacology from the Royal Danish School of Pharmacy. Followng a position as project leader at Neurosearch A/S he became Head of the High-Throughput Screening Section a AstraZeneca CNS & Pain Discovery R&D in Södertälje, Sweden. Dr Witt became Head of Lead Discovery Department at KaroBio AB, Stockholm, Sweden in 2002, becoming Principal Scientist in 2006.